Oxford BioMedica reported that the gene therapy AXO-Lenti-PD, outlicensed to Axovant in June 2018, has been administered to the first patient. The aim of the ongoing clinical study is to evaluate safety and tolerability and collect efficacy data, including standard measures of motor function in patients with Parkinson’s disease.
The study builds on results from the phase I/II trial of ProSavin, which showed six-year durability for reductions in UPDRS Part III “OFF” scores. Initial data from the trial’s first cohort of patients is expected in Q1 2019.
Oxford received a $30m upfront payment, and is eligible to receive $55m on the achievement of certain development milestones and $757.5m upon the achievement of specified regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.